Subtype
Malignant Uterine Neoplasm
CI-CAN-00005955Explore in graph →
824 active trials7 approved drugs44 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005955Explore in graph →
Clinical trials
3,291 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (333)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07418749 | A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer | recruiting | Phase 3 | 398 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07319429 | Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification(FEMUS) | recruiting | Phase 2 / Phase 3 | 260 | Fudan UniversityOTHER |
| 1 |
| Mar 13, 2026 |
| clinicaltrials |
| NCT04697628 | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer(innovaTV 301) | completed | Phase 3 | 502 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 25 | Feb 24, 2026 | clinicaltrials |
| NCT06513065 | Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)(HIPEC-PMP) | recruiting | Phase 3 | 176 | University of SouthamptonOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT03635567 | Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) | completed | Phase 3 | 617 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Feb 4, 2026 | clinicaltrials |
| NCT06671548 | Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | recruiting | Phase 3 | 120 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06712472 | Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer(RAINBO-RED) | recruiting | Phase 3 | 554 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT00980954 | Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy | completed | Phase 3 | 236 | Radiation Therapy Oncology GroupNETWORK | 4 | Dec 31, 2025 | clinicaltrials |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 1,052 | National Cancer Institute (NCI)NIH | 3 | Dec 30, 2025 | clinicaltrials |
| NCT07298642 | Extended-field Proton Therapy for Cervical Cancer | recruiting | Phase 2 / Phase 3 | 44 | National Taiwan University HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06866951 | A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial | withdrawn | Phase 2 / Phase 3 | 0 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05454358 | Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP | terminated | Phase 2 / Phase 3 | 12 | Fudan UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT03422198 | Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer(SAVE) | recruiting | Phase 3 | 188 | University of UtahOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05077215 | Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer | not yet recruiting | Phase 3 | 450 | Evergreen Therapeutics, Inc.INDUSTRY | 0 | Dec 8, 2025 | clinicaltrials |
| NCT05201547 | Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line(DOMENICA) | active not recruiting | Phase 3 | 260 | ARCAGY/ GINECO GROUPOTHER | 10 | Dec 4, 2025 | clinicaltrials |
| NCT06007586 | Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients | completed | Phase 3 | 143 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05445167 | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain | completed | Phase 3 | 89 | Kissei Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT04537156 | Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) | active not recruiting | Phase 3 | 9,327 | Xiamen UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04982237 | A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | active not recruiting | Phase 3 | 445 | AkesoINDUSTRY | 1 | Nov 19, 2025 | clinicaltrials |
| NCT07230626 | SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer | not yet recruiting | Phase 3 | 412 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Nov 17, 2025 | clinicaltrials |
| NCT04111978 | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)(MATAO) | recruiting | Phase 3 | 540 | Swiss GO Trial GroupNETWORK | 3 | Sep 29, 2025 | clinicaltrials |
| NCT07177716 | Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04906993 | Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer | active not recruiting | Phase 3 | 443 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04534075 | Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial(FIDURA) | completed | Phase 3 | 354 | Sahlgrenska University HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06321068 | BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer | terminated | Phase 2 / Phase 3 | 5 | Bio-Thera SolutionsINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT04159155 | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer(CAN-STAMP) | terminated | Phase 2 / Phase 3 | 11 | University Health Network, TorontoOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05862272 | A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | recruiting | Phase 3 | 1,000 | Sumitomo Pharma Switzerland GmbHINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT03728881 | Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial(PRIMAVERA) | completed | Phase 3 | 1,240 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2025 | clinicaltrials |
| NCT00092534 | Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)(FUTURE II) | completed | Phase 3 | 12,167 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 1, 2025 | clinicaltrials |
| NCT03194646 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 6) | terminated | Phase 3 | 1,272 | BayerINDUSTRY | 13 | Jul 28, 2025 | clinicaltrials |
| NCT05056402 | An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old | active not recruiting | Phase 3 | 1,382 | Xiamen UniversityOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT02446652 | Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer | withdrawn | Phase 3 | 0 | National Institute of CancerologíaOTHER_GOV | 1 | May 29, 2025 | clinicaltrials |
| NCT06156514 | Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer(MICHELE) | recruiting | Phase 3 | 140 | National Institute of CancerologíaOTHER_GOV | 1 | May 28, 2025 | clinicaltrials |
| NCT01101451 | Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery | completed | Phase 3 | 340 | GOG FoundationNETWORK | 3 | May 23, 2025 | clinicaltrials |
| NCT03201861 | Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women | recruiting | Phase 3 | 762 | RenJi HospitalOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06459687 | Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer | recruiting | Phase 3 | 440 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT03603184 | Atezolizumab Trial in Endometrial Cancer - AtTEnd(AtTEnd) | completed | Phase 3 | 549 | Mario Negri Institute for Pharmacological ResearchOTHER | 11 | May 9, 2025 | clinicaltrials |
| NCT05179239 | A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer | terminated | Phase 3 | 31 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06641635 | Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer | recruiting | Phase 3 | 440 | Peking Union Medical College HospitalOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06870565 | Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma | not yet recruiting | Phase 3 | 238 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 0 | Mar 17, 2025 | clinicaltrials |
| NCT05440383 | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia | completed | Phase 3 | 287 | Kissei Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06123884 | BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer | recruiting | Phase 2 / Phase 3 | 526 | Bio-Thera SolutionsINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04508309 | Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls | completed | Phase 3 | 1,025 | PATHOTHER | 2 | Jan 30, 2025 | clinicaltrials |
| NCT06781073 | Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma | completed | Phase 3 | 118 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06584032 | Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer | recruiting | Phase 3 | 412 | HutchmedINDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06755515 | A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | enrolling by invitation | Phase 2 / Phase 3 | 510 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06115408 | Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma | completed | Phase 2 / Phase 3 | 40 | Ain Shams UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06732635 | Enhanced Recovery After Surgery (ERAS) for Laparoscopic Hysterectomy at Low Risk Endometrial Cancer(FAST-TRACK) | completed | Phase 3 | 68 | Fundacion para la Formacion e Investigacion Sanitarias de la Region de MurciaOTHER | 1 | Dec 13, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Apr 6, 2026source: clinicaltrials